ANDA 76984, held by Watson Labs. Alendronate Sodium.
As of Nov 16, 2026, ANDA 76984 (Alendronate Sodium), held by Watson Labs, was first approved by FDA on Aug 4, 2008, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 4, 2008 | Original application | Approved | None posted |
| Alendronate SodiumEQ 35MG BASE · tablet;oral | Alendronate Sodium | Rx |
| Alendronate SodiumEQ 40MG BASE · tablet;oral | Alendronate Sodium | Rx |
| Alendronate SodiumEQ 70MG BASE · tablet;oral | Alendronate Sodium | Rx |
| Mar 4, 2016 | Supplement 10Labeling · Standard review | Approved | None posted |
| Mar 4, 2016 | Supplement 14Labeling · Standard review | Approved | None posted |
| May 3, 2013 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jun 29, 2011 | Supplement 7Labeling | Approved | None posted |
| Aug 24, 2010 | Supplement 4Labeling | Approved | None posted |
| Jul 23, 2009 | Supplement 2Labeling | Approved | None posted |
| Aug 4, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters